Taking Perindopril/Indapamida Combix with food, drinks, and alcohol
Take the tablets with a glass of water, preferably in the morning and before meals. Be especially careful if you are on a low-sodium diet. Consult your doctor before taking the tablets.
Pregnancy, lactation, and fertility
If you are pregnant or breastfeeding, or think you may be pregnant, consult your doctor or pharmacist before using this medication.
Pregnancy
Consult your doctor or pharmacist before using any medication.
Consult your doctor if you are (or think you may be) pregnant. Generally, your doctor will advise you to stop taking perindopril/indapamida before becoming pregnant or as soon as possible if you are pregnant and will recommend taking another medication instead of perindopril/indapamida. Perindopril/indapamida is not recommended in the first months of pregnancy and should not be taken after the third month of pregnancy, as it may cause serious harm to your baby if used in this stage of pregnancy.
Lactation
Do not take perindopril/indapamida if you are breastfeeding. Consult your doctor immediately if you are breastfeeding or plan to start breastfeeding.
Driving and operating machinery
This medication does not affect your alertness, but due to the lowering of blood pressure, you may feel dizzy or weak, especially at the beginning of treatment or when increasing the dose. If this occurs, it may affect your ability to drive and operate machinery.
Perindopril/Indapamida Combix contains lactose
If your doctor has told you that you have an intolerance to certain sugars, consult with them before taking this medication.
Follow exactly the administration instructions for this medication as indicated by your doctor. In case of doubt, consult your doctor or pharmacist again.
The recommended dose is one tablet per day.
Take the tablets with a glass of water, preferably in the morning and before meals.
Adults
The usual dose is one tablet once a day.
Senior patients
Your doctor will decide on the best dose for you.
Patients with renal insufficiency
Your doctor may decide to modify the dosing regimen if you suffer from renal insufficiency.
Use in children and adolescents
This medication is not suitable for use in children.
If you take more Perindopril/Indapamida Combix than you should
If you ingest too many tablets, contact your doctor immediately or go to the nearest hospital emergency department. The most common symptom of overdose is a decrease in blood pressure. If a significant decrease in blood pressure occurs (symptoms such as dizziness or fainting), lying down with legs elevated may help.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicological Information Service, phone: 91 562 04 20, indicating the medication and the amount ingested.
If you forgot to take Perindopril/Indapamida Combix
It is essential to take this medication every day, as continuous treatment is more effective. However, if you forgot to take a dose of perindopril/indapamida, take the next dose at the usual time. Do not take a double dose to compensate for the missed dose.
If you interrupt treatment with Perindopril/Indapamida Combix
Since hypertension treatment is usually lifelong, you should talk to your doctor before stopping this medication.
If you have any other questions about using this product, ask your doctor or pharmacist.
If you experience any of the following symptoms, INTERRUPT treatment with this medication and contact your doctor immediately.These are symptoms of asevere allergic reactionand should be treated immediately and usually in ahospital.
swelling of the face, lips, mouth, tongue, eyes, or throat,
Also, contact your doctor immediatelyif you experience any of the following side effects:
Other side effects
Common(may affect up to 1 in 10 people)
Uncommon(may affect up to 1 in 100 people)
If you have systemic lupus erythematosus (a collagen disease), it may worsen.
Rare(may affect up to 1 in 1,000 people)
Very rare(may affect up to 1 in 10,000 people)
Unknown(the frequency cannot be estimated from the available data)
Reporting of adverse effects:
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect that does not appear in this prospectus. You can also report them directly through the Spanish System for the Pharmacovigilance of Medicines for Human Use: https://www.notificaram.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medication.
Keep this medication out of the sight and reach of children.
No special storage conditions are required.
Do not use this medication after the expiration date that appears on the packaging after CAD. The expiration date is the last day of the month indicated.
Do not use this medication if you observe any visible signs of deterioration.
Medications should not be disposed of through drains or in the trash. Dispose of the packaging and medications you no longer need at the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and medications you no longer need. By doing so, you will help protect the environment.
Composition of Perindopril/Indapamida Combix
-The active principles are perindopril terbutilamine and indapamida. Each tablet contains 3.338 mg of perindopril corresponding to 4 mg of perindopril terbutilamine and 1.25 mg of indapamida.
-The other components (excipients) are lactose monohydrate, microcrystalline cellulose (E460i), anhydrous colloidal silica (E551), and magnesium stearate (E470b).
Appearance of the product and content of the packaging
White to off-white, elongated, biconvex, smooth tablets on both faces.
OPA/AL/PVC-Aluminium blister in packs of 30 tablets.
PVC/PVDC-Aluminium blister in packs of 30 tablets.
Holder of the marketing authorization and responsible for manufacturing
Holder of the marketing authorization
Combix Laboratories, S.L.U.
C/ Badajoz 2, Building 2
28223 Pozuelo de Alarcón (Madrid)
Spain
Responsible for manufacturing
Zydus France
ZAC Les Hautes Patures
Parc d'activités des Peupliers
25 Rue des Peupliers
92000 Nanterre
France
or
Centre Specialites Pharmaceutiques
ZAC des Suzots
35 Rue de la Chapelle
63450 Saint Amant Tallende
France
Last review date of this leaflet: November 2021
The detailed and updated information on this medication is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es/.
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.